Laurac Coates News Today

Continuous improvement across all MDA domains was demonstrated over the 100-week timeframe, with approximately 70% of patients achieving near remission in swollen joint count, enthesitis, and the Psoriasis Area and Severity Index (PASI).

Although there are plenty of drugs to treat psoriatic arthritis, and plenty of studies about those drugs individually, there are fewer trials examining strategies to treat patients who fail to respond to methotrexate in the first line. Researchers aimed to fill that knowledge gap with the CONTROL trial.

COSMOS trial results in patients with psoriatic arthritis fit with the expectation that "people whove previously failed a TNF inhibitor might be a little less likely to respond to guselkumab."